Man masturbates next to woman journalist in bus, she beats him up with slippers

Amaravati, Jul 31: Nine people have died after allegedly consuming sanitiser in Prakasam district of Andhra Pradesh today, the police said.

Prakasam district Superintendent of Police Siddharth Kaushal said the people had been consuming sanitiser for the past few days, mixing it with water and soft drinks.

"We are also investigating whether they laced the sanitiser with any other toxic substances," the official said.

"Their family members say these people have been consuming sanitiser for the past ten days. We are sending the sanitiser stocks, being sold in the area, for examination," he added.

Kurichedu in Prakasam district has been under lockdown due to rise in coronavirus cases and hence, liquor shops have also been shut since the past few days.

Habitual drinkers were said to be consuming sanitisers that have alcohol content, apart from illicitly distilled arrack.

The police said two beggars near a temple were the first to fall victim on Thursday night. While one of them was found dead at the spot, another died in the government hospital in Darsi town, they said.

A third person was also taken to the Darsi hospital late on Thursday night after he fell unconscious but he was declared brought dead. Six others who fell ill after allegedly consuming sanitiser, died this morning.

Others who fell ill after consuming sanitiser are undergoing treatment at their residences in the village, the police added.

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.